http://www.thelifesciencesreport.com/pub/co/4251
Kevin DeGeeter, Ladenburg Thalmann (12/12/14) "On Dec. 11, 2014, Mesoblast Ltd.'s partner for development of mesenchymal precursor cells for cardiovascular disease, Teva Pharmaceutical Industries Ltd., held an analyst meeting to provide an outlook for 2015, including an overview of research and development priorities. We believe the presentation significantly derisks development of Mesoblast's cardiovascular franchise and removes a potential overhang from the company's shares."
http://www.thelifesciencesreport.com/pub/co/4251 Kevin DeGeeter,...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |